Multidrug resistance-associated protein 3 and Bcl-2 contribute to multidrug resistance by vinorelbine in lung adenocarcinoma

International Journal of Molecular Medicine

Volumn 28, Issue 6, 2011, Pages 953-960

  Hong, Xuan ^a   Yang, Zhao Yang ^a   Wang, Meng ^a   Lu, Lu ^a   Li, Ying Hong ^a   Hao, Xishan ^b   Chen, Gong Yan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Bcl 2; Lung adenocarcinoma; MRP3; Multidrug resistance; Vinorelbine

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 3; NAVELBINE; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG TREATMENT FAILURE; GENE CONTROL; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT RESPONSE; UNINDEXED SEQUENCE; UPREGULATION; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, ELECTRON, TRANSMISSION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053504137     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.779     Document Type: Article

References (31)

1. Marty M, Extra JM, Espie M, et al: Advances in vinca-alkaloids: Navelbine. Nouv Rev Fr Hematol 31: 77-84, 1989.
2. Rahmani-Jourdheuil D, Coloma F, Placidi M, et al: Human hepatic uptake of two vinca alkaloids: navelbine and vincristine. J Pharm Sci 83: 468-471, 1994. (Pubitemid 24222364)
3. Vokes EE, Rosenberg RK, Jahanzeb M, et al: Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J Clin Oncol 13: 637-644, 1995.
4. Gebbia V, Caruso M, Valenza R, et al: Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma. Anticancer Res 14: 1247-1249, 1994. (Pubitemid 24264169)
5. Green MR: New directions for chemotherapy in non-small-cell lung cancer. Chest 103 (Suppl 4): S370-S372, 1993.
6. Muller M, Meijer C, Zaman GJ, et al: Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91: 13033-13037, 1994.
7. Hipfner DR, Deeley RG and Cole SP: Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461: 359-376, 1999.
8. Chen GY, Yang ZY, Hong X, et al: Establishment of a multi drug-resistant human lung adenocarcinoma cell line and biological characteristics. Zhonghua Yi Xue Za Zhi 87: 924-926, 2007. (Pubitemid 46979353)
9. Rinaldi M, Cauchi C and Gridelli C: First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 17: 64-67, 2006.
10. Domenech GH and Vogel CL: A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2: 113-128, 2001. (Pubitemid 32771563)
11. Harries M and Kaye SB: Recent advances in the treatment of epi thelial ovarian cancer. Expert Opin Investig Drugs 10: 1715-1724, 2001. (Pubitemid 32827430)
12. Devizzi L, Santoro A, Bonfante V, et al: Vinorelbine: a new prom ising drug in Hodgkin's disease. Leuk Lymphoma 22: 409-414, 1996. (Pubitemid 26341006)
13. Weinmann M, Jeremic B, Bamberg M, et al: Treatment of lung cancer in elderly part II: small cell lung cancer. Lung Cancer 40: 1-16, 2003. (Pubitemid 36344062)
14. Bidoli P, Aglione S, Toffolatti L, et al: New strategies in the treatment of esophageal cancer. Minerva Chir 57: 717-731, 2002. (Pubitemid 36313382)
15. He SM, Li R, Kanwar JR, et al: Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem 18: 439-481, 2011.
16. Li X, Li JP, Yuan HY, et al: Recent advances in P-glycoprotein-mediated multidrug resistance reversal mechanisms. Methods Find Exp Clin Pharmacol 29: 607-617, 2007. (Pubitemid 351183141)
17. Borst P and Elferink RO: Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537-592, 2002. (Pubitemid 34800230)
18. Kruh GD and Belinsky MG: The MRP family of drug efflux pumps. Oncogene 22: 7537-7552, 2003. (Pubitemid 37487175)
19. Young LC, Campling BG, Voskoglou-Nomikos T, et al: Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 5: 673-680, 1999. (Pubitemid 29131979)
20. Oguri T, Isobe T, Fujitaka K, et al: Association between expression of the MRP3 gene and exposure to platinum drugs in lung cancer. Int J Cancer 93: 584-589, 2001. (Pubitemid 32701419)
21. Hagmann W, Jesnowski R, Faissner R, et al: ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Up-regulation in 5-fluorouracil-resistant cells. Pancreatology 9: 136-144, 2009.
22. Huang R, Murry DJ, Kolwankar D, et al: Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol 71: 1695-1704, 2006.
23. Wang XB, Wang SS, Zhang QF, et al: Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep 23: 211-215, 2010.
24. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002. (Pubitemid 34161136)
25. Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol 17: 2941-2953, 1999.
26. Zhou F, Yang Y and Xing D: Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 278: 403-413, 2011.
27. Reed JC: Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111: 3322-3330, 2008.
28. Tóthová E, Fricova M, Stecová N, et al: High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma 49: 141-144, 2002. (Pubitemid 34728789)
29. Campos L, Sabido O, Rouault JP, et al: Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84: 595-600, 1994. (Pubitemid 24215962)
30. Bold RJ, Chandra J and McConkey DJ: Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 6: 279-285, 1999. (Pubitemid 29221014)
31. Galante JM, Mortenson MM, Bowles TL, et al: ERK/BCL-2 pathway in the resistance of pancreatic cancer to anoikis. J Surg Res 152: 18-25, 2009.